普拉克索联合左旋多巴治疗帕金森病的临床效果及安全性

马春丽 徐甜颖 王以宁

[摘要]目的 探討普拉克索联合左旋多巴治疗帕金森病的临床效果及安全性。方法 选取2017年1月～2018年12月我院收治的100例帕金森病患者作为研究对象，采用随机抽签法将其分为对照组（50例）和研究组（50例）。对照组患者行左旋多巴治疗方法，研究组患者使用普拉克索联合左旋多巴治疗方法。比较两组患者的临床治疗效果，比较两组患者治疗前后的简明健康状况量表（SF-36）评分、汉密尔顿抑郁量表（HAMD-17）评分，比较两组患者的不良反应发生情况。结果 研究组患者的治疗总有效率高于对照组，差异有统计学意义（P<0.05）;研究组患者治疗后的各项SF-36评分高于对照组，差异有统计学意义（P<0.05）;治疗后，研究组患者的HAMD-17评分低于对照组，差异有统计学意义（P<0.05）;研究组患者的不良反应总发生率低于对照组，差异有统计学意义（P<0.05）。结论 帕金森病应用普拉克索联合左旋多巴治疗，可以有效改善患者的疾病症状，提高临床疗效，且安全性高，有重要的临床应用价值。

[关键词]普拉克索;左旋多巴;帕金森病;临床效果;安全性

[中图分类号] R743.3          [文献标识码] A          [文章编号] 1674-4721（2020）7（a）-0081-04

Clinical efficacy and safety of Pramipexole combined with Levodopa in the treatment of Parkinson′s disease

MA Chun-li1   XU Tian-yin1   WANG Yi-ning2

1. The First Department of Neurology， the Second Affiliated Hospital of Mudanjiang Medical University， Heilongjiang Province， Mudanjiang   157000， China; 2. The First Department of Cardiology， the Second Affiliated Hospital of Mudanjiang Medical University， Heilongjiang Province， Mudanjiang   157000， China

[Abstract] Objective To investigate the clinical effect and safety of Pramipexole combined with Levodopa in the treatment of Parkinson′s disease. Methods From January 2017 to December 2018， 100 patients with Parkinson′s disease treated in our hospital were selected as subjects， and divided into control group （n=50） and study group （n=50） by random lottery method. Patients in the control group were treated with Levodopa， while patients in the study group were treated with Pramipexole combined with Levodopa. The clinical treatment effect of patients of the two groups was compared， the concise health status scale （SF-36） scores and the Hamilton depression scale （HAMD-17） scores of the two groups before and after treatment were compared， and the occurrence of adverse reactions of patients in the two groups was compared. Results The total effective rate of the study group was higher than that of the control group， and the difference was statistically significant （P<0.05）. After treatment， indexes of SF-36 scores in the study group were higher than those in the control group， and the differences were statistically significant （P<0.05）. After treatment， the HAMD-17 score in the study group was lower than that in the control group， with statistically significant difference （P<0.05）. The total incidence of adverse reactions in the study group was lower than that in the control group， and the difference was statistically significant （P<0.05）. Conclusion The application of Pramipexole combined with Levodopa in the treatment of Parkinson′s disease can effectively improve the symptoms of the disease， improve the clinical efficacy， and has high safety. It has important clinical application value.

[Key words] Pramipexole; Levodopa; Parkinson′s disease; Clinical effect; Safety

帕金森病为常见的神经性病变疾病类型，中老年人是帕金森病的多发人群[1-2]。帕金森病患者的运动性症状表现主要包括肌肉强直、反应迟缓、走路姿势障碍、静止状态下震颤表现等，而非运动性症状表现主要包括焦虑、抑郁、认知障碍、睡眠障碍等，对患者的正常生活、生命质量均带来严重危害[3-4]。帕金森病的起病比较隐匿，而且其病情发展缓慢，患者的临床症状表现主要包括静止性震颤现象、姿势步态障碍以及肌强直现象等[5]。目前临床以药物治疗为帕金森病的主要手段[6-7]。本研究选取牡丹江医学院附属第二医院收治的100例帕金森病患者作为研究对象，旨在探讨普拉克索联合左旋多巴治疗帕金森病的临床效果及安全性，现报道如下。……